Lef1 restricts ectopic crypt formation and tumor cell growth in intestinal adenomas.

Saved in:
Bibliographic Details
Title: Lef1 restricts ectopic crypt formation and tumor cell growth in intestinal adenomas.
Authors: Heino S; Translational Cancer Medicine Program (CAN-PRO), iCAN Digital Precision Cancer Medicine Flagship and Wihuri Research Institute, Faculty of Medicine, HiLIFE-Helsinki Institute of Life Science, Biomedicum Helsinki, University of Helsinki, 00014 Helsinki, Finland., Fang S; Translational Cancer Medicine Program (CAN-PRO), iCAN Digital Precision Cancer Medicine Flagship and Wihuri Research Institute, Faculty of Medicine, HiLIFE-Helsinki Institute of Life Science, Biomedicum Helsinki, University of Helsinki, 00014 Helsinki, Finland.; School of Biopharmacy, China Pharmaceutical University, Nanjing 211198, P.R. China., Lähde M; Translational Cancer Medicine Program (CAN-PRO), iCAN Digital Precision Cancer Medicine Flagship and Wihuri Research Institute, Faculty of Medicine, HiLIFE-Helsinki Institute of Life Science, Biomedicum Helsinki, University of Helsinki, 00014 Helsinki, Finland., Högström J; Translational Cancer Medicine Program (CAN-PRO), iCAN Digital Precision Cancer Medicine Flagship and Wihuri Research Institute, Faculty of Medicine, HiLIFE-Helsinki Institute of Life Science, Biomedicum Helsinki, University of Helsinki, 00014 Helsinki, Finland., Nassiri S; Bioinformatics Core Facility, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland., Campbell A; Cancer Research UK Beatson Institute, Garscube Estate, Glasgow G61 1BD, UK.; Institute of Cancer Sciences, Garscube Estate, Glasgow G61 1QH, UK., Flanagan D; Cancer Research UK Beatson Institute, Garscube Estate, Glasgow G61 1BD, UK.; Institute of Cancer Sciences, Garscube Estate, Glasgow G61 1QH, UK., Raven A; Cancer Research UK Beatson Institute, Garscube Estate, Glasgow G61 1BD, UK.; Institute of Cancer Sciences, Garscube Estate, Glasgow G61 1QH, UK., Hodder M; Cancer Research UK Beatson Institute, Garscube Estate, Glasgow G61 1BD, UK.; Institute of Cancer Sciences, Garscube Estate, Glasgow G61 1QH, UK., Nasreddin N; Intestinal Stem Cell Biology Laboratory, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK., Xue HH; Center for Discovery and Innovation, Hackensack University Medical Center, Nutley, NJ 07110, USA., Delorenzi M; Bioinformatics Core Facility, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.; Department of Oncology, University of Lausanne and CHUV, Epalinges, Switzerland.; Ludwig Institute for Cancer Research Lausanne, Epalinges, Switzerland., Leedham S; Intestinal Stem Cell Biology Laboratory, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK., Petrova TV; Department of Oncology, University of Lausanne and CHUV, Epalinges, Switzerland.; Ludwig Institute for Cancer Research Lausanne, Epalinges, Switzerland., Sansom O; Cancer Research UK Beatson Institute, Garscube Estate, Glasgow G61 1BD, UK.; Institute of Cancer Sciences, Garscube Estate, Glasgow G61 1QH, UK., Alitalo K; Translational Cancer Medicine Program (CAN-PRO), iCAN Digital Precision Cancer Medicine Flagship and Wihuri Research Institute, Faculty of Medicine, HiLIFE-Helsinki Institute of Life Science, Biomedicum Helsinki, University of Helsinki, 00014 Helsinki, Finland.
Source: Science advances [Sci Adv] 2021 Nov 19; Vol. 7 (47), pp. eabj0512. Date of Electronic Publication: 2021 Nov 17.
Publication Type: Journal Article
Journal Info: Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101653440 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2375-2548 (Electronic) Linking ISSN: 23752548 NLM ISO Abbreviation: Sci Adv Subsets: MEDLINE; PubMed not MEDLINE
Database: MEDLINE Ultimate
Be the first to leave a comment!
You must be logged in first